Is there still a role for off-pump CABG in 2015? Certainly yes  by Taggart, David P.
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s  there  still  a  role  for  off-pump  CABG  in  2015?  Certainly  yes
Hay todavía un lugar para la cirugía coronaria sin circulación extracorpórea en 2015?
iertamente  sí
avid  P.  Taggart
niversity of Oxford, Dept Cardiac Surgery, Oxford University Hospitals NHS Trust, Oxford OX3 9DU, United KingdomConventional coronary artery bypass grafting using cardiopul-
onary bypass (CPB) and cardioplegic arrest of the heart has been
he gold standard technique for coronary artery bypass grafting
CABG) since the mid  1960s. The major rationale for this approach
s to provide a still, bloodless operating ﬁeld that optimizes the abil-
ty to do a technically perfect operation. Crucially, this technique
lso enables the surgeon to perform a very low risk operation and
everal countries currently report elective mortality rates of around
% for CABG despite the advancing age and comorbidities of the
urgical population.
In the 1980s surgeons from South America1,2 started repor-
ing their experience with off-pump CABG (OPCABG). While their
ork was motivated at least in part by economic considerations, by
erforming CABG without the costs of CPB the operation became
ccessible to a much wider population, it also became evident
hat this approach also had the potential to minimize the dam-
ging affects of CPB. Three decades ago CPB was associated with a
otent systemic inﬂammatory response syndrome, due to activa-
ion of a myriad of cellular and humoral inﬂammatory mediators
s blood circulated through the extracorporeal circuit and was
trongly linked to multi-organ dysfunction and/or failure.3 Fur-
hermore, CPB also generated a large amount of gaseous and
articulate microemboli that was implicated in adverse neurolog-
cal sequelae.4
These reports of OPCABG encouraged a widespread adoption of
his new technique until evidence began to emerge that its pro-
osed beneﬁts did not materialize in randomized trials against
n-pump CABG (ONCABG). Indeed evidence began to accumulate
hat OPCABG could result in signiﬁcantly inferior outcomes when
ompared to ONCABG. Two particular pieces of evidence ques-
ioned the safety and efﬁcacy of OPCABG5,6 and, with the exception
f the Far East, initiated a decline in the numbers of OPCABG world-
ide.
hort term outcomes
The ROOBY trial randomized 2203 patients to ONCABG
nd OPCABG.5 While there was no signiﬁcant difference between
PCABG and ONCABG in the 30-day composite outcome (7.0%
nd 5.6%, respectively; P = 0.19), the 1-year composite outcome
as higher for OPCABG (9.9% vs. 7.4%, P = 0.04) and accompanied
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http://creativecommons.org/licenses/by-nc-nd/4.0/).by fewer grafts completed per patient than originally planned
(17.8% vs. 11.1%, P < 0.001) and lower angiographic graft patency
(82.6% vs. 87.8%, P < 0.01). The trial was, however, subsequently crit-
icized due to the relative inexperience of the participating surgeons
and large numbers of cross-overs.7
In 2012 Moller and colleagues reported a Cochrane Database
systematic review of 86 trials of OPCABG and ONCABG that included
10,716 patients.6 A pooled analysis showed that OPCABG increased
all-cause mortality (3.7% vs. 3.1%; P = 0.04) and resulted in fewer
distal anastomoses (−0.28; 95% CI −0.40 to −0.16, P < .00001) with
no signiﬁcant differences in myocardial infarction, stroke, renal
insufﬁciency, or coronary re-intervention but a reduced incidence
of post-operative atrial ﬁbrillation. The authors concluded ‘Based
on the current evidence, on-pump CABG should continue to be
the standard surgical treatment. However, off-pump CABG may
be acceptable when there are contraindications for cannulation of
the aorta and cardiopulmonary bypass’.
The existing literature has, until recently, consisted of trials
of ONCABG and OPCABG that were individually underpowered to
assess their relative effects on mortality. Two larger trials have
provided greater insights and, crucially so, because the participat-
ing surgeons were, unlike in ROOBY, highly experienced in both
techniques having performed at least 100 OPCABG cases. Lamy and
colleagues8 randomized 4752 patients to ONCABG or OPCABG. At
30 days there was  no signiﬁcant difference in the rate of the primary
composite outcome of death, myocardial infarction, stroke, or new
renal failure requiring dialysis between ONCABG and OPCABG. At
1 year, there was again no signiﬁcant difference in the hazard ratio
(HR) rate of the primary composite outcome (12.1% OPCABG and
13.3% ONCABG: HR with OPCABG 0.91; 95% CI: 0.77–1.07; P = 0.24).
At 1-year repeat coronary revascularization was 1.4% for OPCABG
and 0.8% for ONCABG (HR 1.66; 95% CI, 0.95–2.89; P = 0.07) with
no signiﬁcant differences between the two  groups quality of life
measures or neurocognitive function.
In the German Off-Pump CABG trial in the Elderly (GOPCABE)
2539 patients, aged over 75 years, were randomized to OPCABG
or ONCABG.9 At 30 days there was no signiﬁcant difference in
the respective composite outcome of death, stroke, myocardial
infarction, or new renal-replacement therapy (7.8% vs. 8.2%; HR,
0.95; 95% CI: 0.71–1.28; P = 0.74) or of its individual components.
As for CORONARY repeat revascularization occurred more fre-
quently after OPCABG than ONCABG (1.3% vs. 0.4%; HR, 2.42; 95%
CI, 1.03–5.72; P = 0.04). At 12 months, there was  no signiﬁcant dif-
ference between the groups in the composite end point (13.1% vs.
14.0%; HR, 0.93; 95% CI, 0.76–1.16; P = 0.48) or in any of the indi-
vidual components.
lsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license
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In contrast to the ﬁndings in these large randomized trials
everal large propensity matched databases have reported early
eneﬁts of OPCABG over ONCABG. While these databases have the
dvantage of including tens of thousands of patients and propen-
ity matching for certain risk factors they can still be susceptible to
onfounding factors that may  be known or unknown. Kuss and col-
eagues performed a propensity score analyses of 123,137 patients
ndergoing ONCABG or OPCABG10 and reported that the overall
azard ratio was less than 1 for all outcomes, favoring OPCABG. This
eneﬁt was signiﬁcant for mortality (HR, 0.69; 95% CI: 0.60–0.75),
troke, renal failure, red blood cell transfusion (P < .0001), wound
nfection (P < .001), prolonged ventilation (P < .01), inotropic sup-
ort (P = .02), and intraaortic balloon pump support (P = .05) while
he hazard ratios for myocardial infarction, atrial ﬁbrillation, and
eoperation for bleeding were not signiﬁcant.
Puskas and colleagues11 identiﬁed 876,081 patients from the
TS database of whom 210,469 underwent CABG at sites that had
erformed more than 300 OPCABG and 300 ONCABG during the
-year study period (“high-volume sites”). Outcomes were ana-
yzed both for all sites and for high-volume sites and stratiﬁed by
articipant center and surgeon, and adjusted for 30 variables that
omprise the STS CABG risk model. They reported that OPCABG was
ssociated with a signiﬁcant reduction in risk of death, stroke, acute
enal failure, mortality or morbidity, and postoperative length of
tay.
ong term outcomes
In 2014 Takagi and colleagues reported worse 5-year survival
ith OPCABG.12 From 5 randomized trials and 17 observational
tudies with 104,306 patients, a pooled analysis demonstrated a
% increase in long-term mortality with OPCABG (HR, 1.07; 95%
I, 1.03–1.11; P = .0003). In contrast, the same year, Chaudhry and
olleagues13 reported in a systematic review of 32 studies that
PCABG had similar 5-year survival when compared with ONCABG
HR, 1.06; 95% CI, 0.95–1.19; P = 0.31). They also reported that while
NCABG had a trend toward a 10-year survival advantage (HR, 1.06;
5% CI, 1.00–1.13; P = 0.05) this disappeared when subgroup analy-
is of only randomized controlled trials, registry-based studies, and
ropensity-matched studies was performed.
raft patency
Zhang and colleagues14 examined 12 randomized controlled tri-
ls, for a total of 3894 OPCABG grafts and 4137 ONCABG grafts
erformed during OPCAB and ONCAB. For OPCABG, meta-analysis
howed an increased risk of occlusion of all grafts (HR: 1.35; 95%
I: 1.16–1.57) and saphenous vein grafts (SVGs) (HR, 1.41; 95% CI,
.24–1.60), but no signiﬁcant difference in graft occlusion of left
nternal mammary artery (LIMA) (HR 1.15; 95% CI, 0.83–1.59) and
adial artery (HR 1.37; 95% CI, 0.76–2.47).
eurologic injury
Focal stroke or diffuse neurologic injury, although relatively
ncommon, remains one of the most devastating complications of
ABG. The presence of aortic atherosclerosis has been recognized as
ne of the strongest predictors of overt neurological injury for over
wo decades.15 Avoidance or minimization of aortic manipulation
cannulation, clamping, side biting) has been shown to reduce the
isk of cerebral injury.16 While gross disease and/or calciﬁcation
f the aorta may  be obvious on visual inspection or by palpation,
piaortic scanning is necessary to detect less overt disease and
articularly on the endoluminal surface. We  previously reported
hat any aortic manipulation including the use of side biting clamps 2016;23(1):e1–e3
resulted in an increased number of solid and gaseous microemboli
even from apparently healthy aortas.4 Although the Cochrane
review6 and two  largest randomized trials8,9 reported no signif-
icant difference in the incidence of stroke between ONCABG and
OPCAB two  large propensity matched registries reported a reduc-
tion in stroke with OPCABG.10,11 However none of these studies
addressed the issue of a no touch aortic technique for OPCABG. Mis-
feld and colleagues in meta-analyses of eight observational studies,
including 5619 OPCABG patients who  underwent a no touch aortic
technique reported signiﬁcantly lower neurologic complications
(HR, 0.46; 95% CI, 0.29–0.72; P = .0008) than 5779 ONCABG
patients who experienced some form of aortic manipulation.17
Likewise, Emmert and colleagues18 reported that in comparison
to partial aortic clamping, OPCABG patients undergoing a non-
clamping approach had a signiﬁcantly reduced frequency of stroke
(0.7% vs. 2.3%; HR = 0.39; CI 95%, 0.16–0.90; P = .04) and MACCE
(6.7% vs. 10.8%; HR = 0.55; CI 95%, 0.38–0.79; P = .001), and these
results were similar to those of the control group, who underwent
no-touch total arterial revascularization (stroke rate, 0.8%; MACCE,
7.9%).
Summary
Current evidence from randomized trials strongly indicates that
for most patients undergoing contemporary bypass grafting there
is little to choose between ONCABG and OPCABG in terms of patient
safety. This is however predicated on the assumption that the
OPCABG surgeon is highly experienced in this technically more
challenging method because there is robust evidence, that in the
hands of inexperienced surgeons, OPCABG leads to a high rate of
cross overs and less complete revascularization. Even when per-
formed by experienced surgeons OPCABG may result in inferior
venous graft patency (possibly due to the loss of the anti-platelet
effect of CPB and so dual antiplatelet medication is recommended).
On the other hand, there is good evidence that OPCABG when incor-
porating a no touch aortic technique can signiﬁcantly reduce the
risk of stroke. In contrast to randomized trials large propensity
matched registries have reported that OPCABG reduces postop-
erative mortality and most aspects of morbidity. Lastly, although
there is conﬂicting evidence whether OPCABG reduces long-term
survival this is almost certainly true if performed by inexperienced
surgeons who  do not achieve complete revascularization.
So why is there still ﬁrmly a place for OPCABG in 2015? The
answer is simple: it is because there are, undoubtedly, certain
cohorts of patients who do beneﬁt from OPCABG e.g. patients with
heavily diseased calciﬁed or porcelain aortas who are at high risk
of stroke from any aortic manipulation. However to be able to per-
form OPCABG consistently safely and efﬁciently in such situations
it is essential that the surgeon is conﬁdent and proﬁcient with the
technique. The dilemma, however, is that to achieve this level of
competency it requires that the surgeon performs the operation
regularly as no occasional operation is a good operation. The mantra
from some surgeons that ‘I reserve OPCABG’ for my  difﬁcult cases is
illogical as the worst time to change technique is when faced with
a difﬁcult operation. This also raises the question of whether this
technique for CABG should be considered a sub-specialty allow-
ing some surgeons to gain the appropriate expertise and to teach
trainees. A ﬁnal concluding thought is that, in terms of overall ben-
eﬁts to most patients undergoing CABG, it is far more important to
use two internal mammary arteries, because of their superior sur-
vival advantage,19 than whether the operation is performed on or
off pump.Conﬂict of interests
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